Bellevue Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$95.5K Buy
685
+3
+0.4% +$420 0.05% 114
2025
Q4
$83.8K Buy
682
+3
+0.4% +$365 0.03% 115
2025
Q3
$75.4K Buy
679
+3
+0.4% +$341 0.03% 122
2025
Q2
$75K Buy
676
+3
+0.4% +$319 0.04% 122
2025
Q1
$75.5K Buy
673
+2
+0.3% +$206 0.04% 120
2024
Q4
$62K Buy
671
+65
+11% +$5.85K 0.03% 134
2024
Q3
$50.8K Buy
606
+2
+0.3% +$153 0.03% 160
2024
Q2
$41.5K Buy
604
+4
+0.7% +$267 0.02% 164
2024
Q1
$44K Sell
600
-164
-21% -$12.6K 0.03% 163
2023
Q4
$61.9K Buy
764
+4
+0.5% +$311 0.05% 128
2023
Q3
$57K Sell
760
-222
-23% -$17.1K 0.04% 124
2023
Q2
$75.7K Buy
982
+3
+0.3% +$239 0.05% 107
2023
Q1
$81.2K Buy
979
+3
+0.3% +$248 0.06% 101
2022
Q4
$82.9K Hold
976
0.06% 107
2022
Q3
$60K Buy
976
+8
+0.8% +$504 0.05% 135
2022
Q2
$60K Buy
968
+5
+0.5% +$310 0.04% 140
2022
Q1
$58K Buy
963
+2
+0.2% +$128 0.04% 154
2021
Q4
$70K Sell
961
-171
-15% -$11.8K 0.04% 144
2021
Q3
$80K Buy
1,132
+78
+7% +$5.48K 0.05% 135
2021
Q2
$73K Buy
1,054
+2
+0.2% +$134 0.04% 149
2021
Q1
$68K Hold
1,052
0.04% 151
2020
Q4
$71K Buy
1,052
+52
+5% +$3.14K 0.04% 146
2020
Q3
$63K Buy
1,000
+250
+33% +$17.3K 0.04% 139
2020
Q2
$58K Buy
750
+75
+11% +$5.75K 0.06% 146
2020
Q1
$53K Buy
675
+50
+8% +$3.46K 0.06% 160
2019
Q4
$41K Buy
+625
New +$40.7K 0.03% 169

Other funds holding GILD

Bellevue Asset Management's GILD Position: Q1 2026 in Review

Bellevue Asset Management increased its Gilead Sciences (GILD) stake by 0.44% in Q1 2026, buying an estimated $420 and bringing the position to 685 shares worth $95.5K. The position accounts for 0.05% of the portfolio, ranked #114.

Bellevue Asset Management first reported a position in GILD in Q4 2019 and has held it in 26 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Bellevue Asset Management held 685 shares of Gilead Sciences worth $95.5K as of Q1 2026.
  • Bellevue Asset Management bought 3 Gilead Sciences shares in Q1 2026, an estimated $420.
  • Gilead Sciences made up 0.05% of Bellevue Asset Management's portfolio in Q1 2026, its #114 holding.
  • Bellevue Asset Management first reported a position in Gilead Sciences in Q4 2019 and has held it in 26 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Bellevue Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.